Martinsried, Germany, May 24, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K. Under this collaboration Proteros will apply its know-how, experience of structural analysis and its proprietary X-ray crystallography platform to support IP-K's mission to develop therapeutics for infectious diseases.
Cony D'Cruz, Chief Business Officer of Proteros, stated, "Institut Pasteur Korea is a world class translational research institute, renowned as a centre of excellence in biomedical research and technology development with a clear focus on infectious and neglected disease. We welcome the opportunity for Proteros to contribute to these efforts."
Dr. Michel Liuzzi, Director, Early Discovery Program at IP-K, added "We are very pleased with the expertise and know-how of Proteros in providing timely X-ray crystallography support to our in-house drug discovery projects and we look forward to continue collaborating with Proteros in the future."
About Institut Pasteur Korea:
Institut Pasteur Korea (IP-K) is an independent non-profit institute founded in April, 2004 with a strategic focus on enabling technologies and therapeutic development in disease models pertaining to public health. IP-K has developed a novel research platform that combines chemical genomics with high content visual screening by bringing together the latest advances in biology, technology, and chemistry. The application of the platform technology in the fields of infectious disease and chronic illness allows basic science to be extended to drug discovery. In turn the application of functional genomics - using global siRNA - allows further elucidation of the basic molecular and genetic underpinnings of disease. Visit http://www.
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables 'knowledge driven lead engineering' to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients' internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.